Atlas Trials

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Clinical trial NCT03410992 · COMPLETED

Trial details

NCT number
NCT03410992
Sponsor
UCB Biopharma SRL
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Chronic Plaque PsoriasisModerate to Severe Chronic Plaque PsoriasisPsoriatic Arthritis
Start date
2018-02-05
Primary completion
2018-12-28
Enrollment
435

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.